Trends in atopic dermatitis-from standard pharmacotherapy to novel drug delivery systems

Detalhes bibliográficos
Autor(a) principal: Souto, Eliana B.
Data de Publicação: 2019
Outros Autores: Dias-Ferreira, João, Oliveira, Jéssica, Sanchez-Lopez, Elena, Lopez-Machado, Ana, Espina, Marta, Garcia, Maria L., Souto, Selma B., Martins-Gomes, Carlos, Silva, Amélia M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/1822/62213
Resumo: Atopic dermatitis (AD) is a predominant and deteriorating chronic inflammation of the skin, categorized by robust burning and eczematous lacerations in diverse portions of the body. AD affects about 20% of both offspring and adults worldwide. The pathophysiology of AD combines environmental, hereditary, and immunological aspects, together with skin barrier dysfunction. The procedures used to prevent the disease are the everyday usage of creams to support the restoration of the epidermal barrier. The classical treatments include the use of topical corticosteroids as a first-line therapy, but also calcineurin inhibitors, antihistamines, antibiotics, phototherapy, and also immunosuppressant drugs in severe cases of AD. Topical drug delivery to deeper skin layers is a difficult task due to the skin anatomic barrier, which limits deeper penetration of drugs. Groundbreaking drug delivery systems, based on nanoparticles (NPs), have received much attention due to their ability to improve solubility, bioavailability, diffusion, targeting to specific types of cells, and limiting the secondary effects of the drugs employed in the treatment of AD. Even so, additional studies are still required to recognize the toxicological characteristics and long-term safety of NPs. This review discusses the current classical pharmacotherapy of AD against new nanoparticle skin delivery systems and their toxicologic risks.
id RCAP_73ef63989a9cc71f82fa547ffbcd5dc2
oai_identifier_str oai:repositorium.sdum.uminho.pt:1822/62213
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Trends in atopic dermatitis-from standard pharmacotherapy to novel drug delivery systemsatopic dermatitisdrug delivery systemspharmacological treatmentnanotechnologynanoparticlesScience & TechnologyAtopic dermatitis (AD) is a predominant and deteriorating chronic inflammation of the skin, categorized by robust burning and eczematous lacerations in diverse portions of the body. AD affects about 20% of both offspring and adults worldwide. The pathophysiology of AD combines environmental, hereditary, and immunological aspects, together with skin barrier dysfunction. The procedures used to prevent the disease are the everyday usage of creams to support the restoration of the epidermal barrier. The classical treatments include the use of topical corticosteroids as a first-line therapy, but also calcineurin inhibitors, antihistamines, antibiotics, phototherapy, and also immunosuppressant drugs in severe cases of AD. Topical drug delivery to deeper skin layers is a difficult task due to the skin anatomic barrier, which limits deeper penetration of drugs. Groundbreaking drug delivery systems, based on nanoparticles (NPs), have received much attention due to their ability to improve solubility, bioavailability, diffusion, targeting to specific types of cells, and limiting the secondary effects of the drugs employed in the treatment of AD. Even so, additional studies are still required to recognize the toxicological characteristics and long-term safety of NPs. This review discusses the current classical pharmacotherapy of AD against new nanoparticle skin delivery systems and their toxicologic risks.This work was financially supported by the Portuguese Science and Technology Foundation (FCT/MCT) and from European Funds (PRODER/COMPETE) under the project reference M-ERA-NET/0004/2015-PAIRED and UID/AGR/04033/2019 (CITAB), co-financed by FEDER, under the Partnership Agreement PT2020, and also by the Institute of Nanoscience and Nanotechnology under the project ART (2018).info:eu-repo/semantics/publishedVersionMDPIUniversidade do MinhoSouto, Eliana B.Dias-Ferreira, JoãoOliveira, JéssicaSanchez-Lopez, ElenaLopez-Machado, AnaEspina, MartaGarcia, Maria L.Souto, Selma B.Martins-Gomes, CarlosSilva, Amélia M.2019-11-122019-11-12T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/1822/62213engSouto, Eliana; Dias-Ferreira, João; Oliveira, Jéssica; Sanchez-Lopez, Elena; Lopez-Machado, Ana; Espina, Marta; Garcia, Maria L.; Souto, Selma B.; Martins-Gomes, Carlos; Silva, Amélia M., Trends in atopic dermatitis-from standard pharmacotherapy to novel drug delivery systems. International Journal of Molecular Sciences, 20(22), 5659, 20191424-67831422-00671661-659610.3390/ijms2022565931726723http://www.mdpi.com/journal/ijmsinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:48:54Zoai:repositorium.sdum.uminho.pt:1822/62213Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T19:47:14.919462Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Trends in atopic dermatitis-from standard pharmacotherapy to novel drug delivery systems
title Trends in atopic dermatitis-from standard pharmacotherapy to novel drug delivery systems
spellingShingle Trends in atopic dermatitis-from standard pharmacotherapy to novel drug delivery systems
Souto, Eliana B.
atopic dermatitis
drug delivery systems
pharmacological treatment
nanotechnology
nanoparticles
Science & Technology
title_short Trends in atopic dermatitis-from standard pharmacotherapy to novel drug delivery systems
title_full Trends in atopic dermatitis-from standard pharmacotherapy to novel drug delivery systems
title_fullStr Trends in atopic dermatitis-from standard pharmacotherapy to novel drug delivery systems
title_full_unstemmed Trends in atopic dermatitis-from standard pharmacotherapy to novel drug delivery systems
title_sort Trends in atopic dermatitis-from standard pharmacotherapy to novel drug delivery systems
author Souto, Eliana B.
author_facet Souto, Eliana B.
Dias-Ferreira, João
Oliveira, Jéssica
Sanchez-Lopez, Elena
Lopez-Machado, Ana
Espina, Marta
Garcia, Maria L.
Souto, Selma B.
Martins-Gomes, Carlos
Silva, Amélia M.
author_role author
author2 Dias-Ferreira, João
Oliveira, Jéssica
Sanchez-Lopez, Elena
Lopez-Machado, Ana
Espina, Marta
Garcia, Maria L.
Souto, Selma B.
Martins-Gomes, Carlos
Silva, Amélia M.
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universidade do Minho
dc.contributor.author.fl_str_mv Souto, Eliana B.
Dias-Ferreira, João
Oliveira, Jéssica
Sanchez-Lopez, Elena
Lopez-Machado, Ana
Espina, Marta
Garcia, Maria L.
Souto, Selma B.
Martins-Gomes, Carlos
Silva, Amélia M.
dc.subject.por.fl_str_mv atopic dermatitis
drug delivery systems
pharmacological treatment
nanotechnology
nanoparticles
Science & Technology
topic atopic dermatitis
drug delivery systems
pharmacological treatment
nanotechnology
nanoparticles
Science & Technology
description Atopic dermatitis (AD) is a predominant and deteriorating chronic inflammation of the skin, categorized by robust burning and eczematous lacerations in diverse portions of the body. AD affects about 20% of both offspring and adults worldwide. The pathophysiology of AD combines environmental, hereditary, and immunological aspects, together with skin barrier dysfunction. The procedures used to prevent the disease are the everyday usage of creams to support the restoration of the epidermal barrier. The classical treatments include the use of topical corticosteroids as a first-line therapy, but also calcineurin inhibitors, antihistamines, antibiotics, phototherapy, and also immunosuppressant drugs in severe cases of AD. Topical drug delivery to deeper skin layers is a difficult task due to the skin anatomic barrier, which limits deeper penetration of drugs. Groundbreaking drug delivery systems, based on nanoparticles (NPs), have received much attention due to their ability to improve solubility, bioavailability, diffusion, targeting to specific types of cells, and limiting the secondary effects of the drugs employed in the treatment of AD. Even so, additional studies are still required to recognize the toxicological characteristics and long-term safety of NPs. This review discusses the current classical pharmacotherapy of AD against new nanoparticle skin delivery systems and their toxicologic risks.
publishDate 2019
dc.date.none.fl_str_mv 2019-11-12
2019-11-12T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/1822/62213
url http://hdl.handle.net/1822/62213
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Souto, Eliana; Dias-Ferreira, João; Oliveira, Jéssica; Sanchez-Lopez, Elena; Lopez-Machado, Ana; Espina, Marta; Garcia, Maria L.; Souto, Selma B.; Martins-Gomes, Carlos; Silva, Amélia M., Trends in atopic dermatitis-from standard pharmacotherapy to novel drug delivery systems. International Journal of Molecular Sciences, 20(22), 5659, 2019
1424-6783
1422-0067
1661-6596
10.3390/ijms20225659
31726723
http://www.mdpi.com/journal/ijms
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799133045787197440